HOOKIPA Pharma Statistics
Total Valuation
HOOKIPA Pharma has a market cap or net worth of $70.77 million. The enterprise value is -$38.13 million.
| Market Cap | 70.77M |
| Enterprise Value | -38.13M |
Important Dates
The next estimated earnings date is Thursday, May 9, 2024, before market open.
| Earnings Date | May 9, 2024 |
| Ex-Dividend Date | n/a |
Share Statistics
HOOKIPA Pharma has 96.55 million shares outstanding. The number of shares has increased by 53.43% in one year.
| Shares Outstanding | 96.55M |
| Shares Change (YoY) | +53.43% |
| Shares Change (QoQ) | n/a |
| Owned by Insiders (%) | 19.59% |
| Owned by Institutions (%) | 39.38% |
| Float | 58.31M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 3.60 |
| Forward PS | 2.66 |
| PB Ratio | 0.81 |
| P/FCF Ratio | n/a |
| PEG Ratio | n/a |
Enterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 3.50, with a Debt / Equity ratio of 0.07.
| Current Ratio | 3.50 |
| Quick Ratio | 3.25 |
| Debt / Equity | 0.07 |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | -255.19 |
Financial Efficiency
Return on equity (ROE) is -85.70% and return on invested capital (ROIC) is -101.33%.
| Return on Equity (ROE) | -85.70% |
| Return on Assets (ROA) | -48.00% |
| Return on Capital (ROIC) | -101.33% |
| Revenue Per Employee | $133,305 |
| Profits Per Employee | -$540,265 |
| Employee Count | 151 |
| Asset Turnover | 0.12 |
| Inventory Turnover | n/a |
Taxes
In the past 12 months, HOOKIPA Pharma has paid $368,000 in taxes.
| Income Tax | 368,000 |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has increased by +3.37% in the last 52 weeks. The beta is 1.02, so HOOKIPA Pharma's price volatility has been similar to the market average.
| Beta (1Y) | 1.02 |
| 52-Week Price Change | +3.37% |
| 50-Day Moving Average | 0.73 |
| 200-Day Moving Average | 0.67 |
| Relative Strength Index (RSI) | 50.49 |
| Average Volume (30 Days) | 543,077 |
Short Selling Information
The latest short interest is 315,905, so 0.33% of the outstanding shares have been sold short.
| Short Interest | 315,905 |
| Short Previous Month | 333,389 |
| Short % of Shares Out | 0.33% |
| Short % of Float | 0.54% |
| Short Ratio (days to cover) | 0.65 |
Income Statement
In the last 12 months, HOOKIPA Pharma had revenue of $20.13 million and -$81.58 million in losses. Loss per share was -$0.86.
| Revenue | 20.13M |
| Gross Profit | 20.13M |
| Operating Income | -97.69M |
| Pretax Income | -81.21M |
| Net Income | -81.58M |
| EBITDA | -77.34M |
| EBIT | -80.90M |
| Loss Per Share | -$0.86 |
Balance Sheet
The company has $117.10 million in cash and $6.56 million in debt, giving a net cash position of $110.54 million or $1.14 per share.
| Cash & Cash Equivalents | 117.10M |
| Total Debt | 6.56M |
| Net Cash | 110.54M |
| Net Cash Per Share | $1.14 |
| Equity / Book Value | 89.86M |
| Book Value Per Share | 0.93 |
| Working Capital | 105.13M |
Cash Flow
In the last 12 months, operating cash flow was -$57.52 million and capital expenditures -$4.16 million, giving a free cash flow of -$61.68 million.
| Operating Cash Flow | -57.52M |
| Capital Expenditures | -4.16M |
| Free Cash Flow | -61.68M |
| FCF Per Share | -$0.74 |
Margins
Gross margin is 100.00%, with operating and profit margins of -485.34% and -405.29%.
| Gross Margin | 100.00% |
| Operating Margin | -485.34% |
| Pretax Margin | -403.46% |
| Profit Margin | -405.29% |
| EBITDA Margin | -384.24% |
| EBIT Margin | -401.88% |
| FCF Margin | -306.44% |
Dividends & Yields
HOOKIPA Pharma does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -53.43% |
| Shareholder Yield | -53.43% |
| Earnings Yield | -112.67% |
| FCF Yield | -85.19% |
Analyst Forecast
The average price target for HOOKIPA Pharma is $4.44, which is 505.73% higher than the current price. The consensus rating is "Strong Buy".
| Price Target | $4.44 |
| Price Target Difference | 505.73% |
| Analyst Consensus | Strong Buy |
| Analyst Count | 4 |
| Revenue Growth Forecast (5Y) | 69.44% |
| EPS Growth Forecast (5Y) | n/a |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
HOOKIPA Pharma has an Altman Z-Score of -3.34 and a Piotroski F-Score of 2. A Z-score under 3 suggests an increased risk of bankruptcy.
| Altman Z-Score | -3.34 |
| Piotroski F-Score | 2 |